iShares Genomics Immunology and Healthcare ETF
IDNA
53 hedge funds and large institutions have $41.3M invested in iShares Genomics Immunology and Healthcare ETF in 2024 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 21 reducing their positions, and 11 closing their positions.
3.85% less ownership
Funds ownership: 33.33% → 29.48% (-3.9%)
8% less capital invested
Capital invested by funds: $45.1M → $41.3M (-$3.75M)
15% less funds holding
Funds holding: 62 → 53 (-9)
55% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 11
62% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$2.33M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$438K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$293K |
| 4 |
OIA
OneDigital Investment Advisors
Overland Park,
Kansas
|
+$250K |
| 5 |
AWM
Avior Wealth Management
Omaha,
Nebraska
|
+$232K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$4.23M |
| 2 |
Morgan Stanley
New York
|
-$1.72M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$903K |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$461K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$392K |
IDNA Hedge Fund Activity: Q3 2024 in Review
53 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in iShares Genomics Immunology and Healthcare ETF (IDNA) for Q3 2024, worth a combined $41.3M — down 8.3% from $45.1M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of IDNA and 5 opened new positions — a net loss of 6 holders — while 21 trimmed existing stakes and 8 added.
The largest buyer was UBS Group, adding an estimated $2.33M. The largest seller was Jane Street, exiting entirely with an estimated $4.23M sold.
- 53 institutional investors held iShares Genomics Immunology and Healthcare ETF (IDNA) as of Q3 2024, down from 62 in Q2 2024.
- Funds reported $41.3M of iShares Genomics Immunology and Healthcare ETF stock for Q3 2024, down 8.3% quarter-over-quarter.
- 5 funds opened new iShares Genomics Immunology and Healthcare ETF positions in Q3 2024 and 11 closed out, a net change of -6 holders.
- The largest iShares Genomics Immunology and Healthcare ETF buyer in Q3 2024 was UBS Group, an estimated $2.33M added.
- The largest iShares Genomics Immunology and Healthcare ETF seller in Q3 2024 was Jane Street, an estimated $4.23M sold.
Based on aggregated 13F filings for Q3 2024.